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Jinmei Yao†, Ying Zhao†, Juanwen Zhang*, Yani Hong, Huanle Lu and Jianping WuAbstract
Background: Low serum amylase levels have been reported in patients with metabolic syndrome (MS), diabetes,
and asymptomatic non-alcoholic fatty liver disease (NAFLD). However, no study has yet indicated the serum amylase
levels in NAFLD with MS. The aim of the present study was to evaluate serum amylase levels in NAFLD patients with
and without MS, and to explore a possible association between serum amylase levels with the components of MS and
the degree of hepatic fibrosis in NAFLD patients.
Methods: Our study included 713 NAFLD participants (180 females and 533 males) and 304 healthy control
participants (110 females and 194 males). The diagnosis of NAFLD was based on ultrasonography, and advanced
fibrosis was assessed by the FIB-4 index.
Results: Serum amylase levels were significantly lower in NAFLD patients with MS compared with NAFLD patients
without MS and healthy controls (42, 45, and 53 IU/L, respectively). The serum amylase levels of patients with
elevated glucose, elevated triglycerides, and low high density lipoprotein cholesterol patients were significantly
lower than in case of normal parameters (both p < 0.05). Multivariate logistic regression analysis showed that a
relative serum amylase level increase was an independent factor predicting advanced fibrosis (FIB-4 ≥1.3) in
NAFLD participants (OR: 1.840, 95% CI: 1.117-3.030, p=0.017).
Conclusions: Compared with NAFLD patients without MS and healthy controls, serum amylase levels were
significantly lower in NAFLD patients with MS. Moreover, a relative serum amylase increase may be an independent
factor of more advanced hepatic fibrosis.
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NAFLD is a clinico-pathological condition and corre-
sponds to a disease spectrum encompassing simple steato-
sis, nonalcoholic steatohepatitis (NASH) with or without
cirrhosis, and hepatocellular carcinoma (HCC) [1-5]. Ap-
proximately, 5% to 20% of patients with NAFLD develop
NASH, which progresses to advanced fibrosis in 10% to
20% of cases and cirrhosis in nearly 5% of cases [3,4,6].
The prevalence of NAFLD in the general population in
Europe is estimated to be 20% to 30% [7], and 12% to 24%
in Asia [8]. In Shanghai, Guangdong, and Hong Kong
(China) it has been reported to be 17%, 15%, and 16%,
respectively [9-11].* Correspondence: tym2011@yeah.net
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unless otherwise stated.NAFLD is closely associated with obesity, type 2 dia-
betes mellitus, metabolic syndrome (MS), insulin resist-
ance, hypertension and dyslipidemia [12]. However, it is
worth noting that nonalcoholic steatohepatitis also in-
duces and enhances insulin resistance, leading to a vi-
cious cycle [6]. Patients with NAFLD exhibit increased
liver-related complications and mortality [6]. NAFLD
has become a significant public health burden owing to
hepatic and extrahepatic morbidity and mortality [2,13].
The gold standard of hepatic fibrosis remains liver bi-
opsy, but this technique is potentially risky and expen-
sive [14]. Adams et al. [14] found that the FIB-4 index
was the most appropriate indicator for advanced fibrosis
prediction compared with other non-invasive fibrosis
models. Likewise, Xun et al. found that the FIB-4 index,
although slightly less accurate than liver biopsy, can be. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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patients [15].
Elevated serum amylase remains the most widely used
biochemical test for the diagnosis of acute pancreatitis
with serum amylase levels ≥ 3 times the normal upper
limit [16,17]. Low serum amylase has been reported in
diffuse pancreas destruction and/or atrophic pancreas
tissue [18-21]. Recently, other studies [22-26] have shown
that lower serum amylase levels are associated with an
increased prevalence for MS, diabetes, and NAFLD in
asymptomatic adults and suggested that insulin resist-
ance and fat accumulation may result in a decrease of
serum amylase levels. Morever, Nakajima K et al. indicated
that low serum amylase may be a marker for moderate or
severe NAFLD [25].
Since NAFLD and MS can each lead to the decrease
of serum amylase levels, we hypothesized that the com-
bination of NAFLD and MS could further accentuate
this decrease. Therefore, we aimed to explore the diag-
nostic value of serum amylase levels in the context of




This study was approved by the ethics committee of
the First Affiliated Hospital of the Medical College at
Zhejiang University in China and was performed in
accordance with the Helsinki Declaration. Written in-
formed consent was obtained from each participant at
the time of enrollment.
Inclusion and exclusion criteria
The diagnosis of MS was based on the Chinese Diabetes
Society (CDS) classification when any three or more
of the following five components were present [27]:
(i) body mass index (BMI) ≥ 25 kg/m2 ; (ii) fasting plasma
glucose (FPG) ≥ 6.1 mmol/L or taking anti-diabetic medi-
cations; (iii) blood pressure ≥ 140/90 mmHg or taking
anti-hypertensive medications; (iv) triglycerides (TG) ≥ 1.7
mmol/L; and (v) high density lipoprotein cholesterol
(HDL-c) < 0.9 mmol/L in males or < 1.0 mmol/L in
females. Diabetes diagnosis was based on the 2010
International Expert Committee (IEC) and the American
Diabetes Association (ADA) guidelines [28]. Diabetes mel-
litus was identified according to the following compo-
nents: HbA1c ≥ 6.5%; random plasma glucose or 2-hour
glucose ≥ 11.1 mmol/L; and fasting plasma glucose ≥
7.0 mmol/dL. NAFLD was diagnosed according to the
guidelines established for the diagnosis and treatment
of NAFLD issued by the Chinese National Consensus
Workshop on Nonalcoholic Fatty Liver Disease [29]. The
diagnosis of NAFLD was based on ultrasonography
finding of hepatic steatosis as diagnosed by characteristicecho patterns using a Toshiba Nemio 20 sonography
machine with a 3.5-MHz probe (Toshiba, Tokyo, Japan).
Hepatic steatosis was identified according to characteris-
tics of the echo patterns, such as ultrasound beam at-
tenuation, diffuse hyper echogenicity of the liver, and
poor visualization of intra hepatic structures [30]. Pa-
tients with any of the following conditions in their medical
history were excluded from the study: (i) alcohol consump-
tion greater than 140 g/week for men and 70 g/week
for women; (ii) viral hepatitis or autoimmune hepa-
titis; or (iii) hepatotoxic medications [31].
Healthy control participants were selected from clinically
asymptomatic participants after exclusion of the following
conditions: kidney, cardiovascular, liver, respiratory, and
gynecologic diseases, impaired glucose tolerance, arterial
hypertension, body mass index (BMI) ≥ 28 kg/m2 or ≤ 18.5
kg/m2, abnormal triglycerides (≥ 2.26 mmol/L) or total
cholesterol (≥ 6.22 mmol/L), smoking (≥ 20 cigarettes per
day) or drinking (≥ 30 g per day), the presence of preg-
nancy or lactation, surgery during the previous six months,
acute or chronic infections, history of malignancy or drug
intake within the previous two weeks.
Our study included 713 NAFLD participants (180 fe-
males [50.8 ± 13.4 years] and 533 males [44.5 ± 11.2 years])
and 304 healthy control participants (110 females [46.7 ±
11.5 years] and 194 males [46.0 ± 10.1 years]) who under-
went a general health checkup in the context of the Health
Care Centre at the First Affiliated Hospital of Medical
College of Zhejiang University between September 2013
and February 2014. We divided the NAFLD participants
into two groups: (1) NAFLD with MS (N = 300) and (2)
NAFLD without MS (N = 413).
Clinical and biochemical assessment
All study participants had a physical examination that
included anthropometry, blood pressure measurement,
and health habit inventory. Systolic blood pressure (SBP)
and diastolic blood pressure (DBP) were measured using
an automated sphygmomanometer with the subject in a
sitting position. Body mass index (BMI) was calculated
according to the following equation: body weight (kg) di-
vided by the square of the height (m2). FIB-4 index was
calculated according to the following equation:





All study participants were subjected to the following
biochemical determinations: serum amylase, alanine ami-
notransferase (ALT), aspartate aminotransferase (AST),
triglyceride (TG), total cholesterol (TC), high density
lipoprotein cholesterol (HDL-c), low density lipoprotein
cholesterol (LDL-c), γ-glutamyltransferase ( γ-GT), FPG,
creatinine (Cr), uric acid (UA), high sensitivity C reactive
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hemoglobin A1C (HbA1C) measurements.
All venous blood samples were obtained in the morn-
ing following a 12 h fast. Serum amylase, ALT, AST, TG,
TC, HDL-c, LDL-c, γ -GT, and FPG were determined
using a Hitachi DDP autoanalyzer (Hitachi Corp, Ibaragi,
Japan). ALT, AST, TG, TC, γ -GT, and FPG levels were
measured using Roche reagents (Roche Diagnostics,
Indianapolis, USA). Serum amylase, HDL-c and LDL-c
levels were measured using Shenshuoyoufu reagents
(Shenshuoyoufu, Shanghai, China). HbA1c was deter-
mined on a Sysmex HbA1c analyzer G8 (Sysmex cor-
poration, Kobe, Japan) using Sysmex reagents. PLT count
was determined using a Sysmex XE-2100 automated
hematology analyzer (Sysmex Corp, Kobe, Japan).
Evaluation of liver fibrosis
No liver biopsy was performed. Instead, a non-invasive
FIB-4 index of ≥1.3 was utilized to evaluate advanced fi-
brosis in NAFLD patients (defined as portal fibrosis with
many septa and cirrhosis [14,32]), according to studies
by Xun et al. and Kim et al. [15,33].
Statistical analyses
Statistical analyses were performed using SPSS, version
16 (SPSS, Inc., Chicago, USA). Age, BMI, SBP, DBP, TC,Table 1 Baseline characteristics of study participants
Variables NAFLD (n = 713)
Without MS (n = 413) W
Age (yr) 45.9 ± 12.1
Gender (female/male) 132/281#
BMI (kg/m2) 25.9 ± 2.7*#
SBP (mmHg) 131± 16*
DBP (mmHg) 80 ± 11*
ALT (IU/L) 26 (7–179)*#
AST (IU/L) 24 (12–103)*#
γ-GT (IU/L) 29 (8–248)*#
TG (mmol/L) 1.32 (0.34–3.74)*# 2
TC (mmol/L) 4.91 ± 0.91*#
HDL-c (mmol/L) 1.24 ± 0.34*#
LDL-c (mmol/L) 2.74 ± 0.57*#
FPG (mmol/L) 5.21 (3.82–7.52)*# 5
Cr (μmol/L) 73 (37–104) #
UA (μmol/L) 351 (66–548)*#
Amylase (IU/L) 45 (21–207)*#
HbA1C (%) 5.6 (4.2–6.9)*#
HsCRP (mg/L) 1.4 (0.3–19.4)*#
PLT (109/L) 233 ± 52*
Data are presented as mean ±SD or median (range).
P value: compared among three groups.
*p<0.05, compared with controls, #p<0.05, NAFLD without MS compared with NAFLHDL-c, LDL-c, FPG, and PLT count were reported as
mean ± standard deviation (SD). Serum amylase, ALT,
AST, γ -GT, TG, Cr, UA, HbA1C, HsCRP, and FIB-4
index were reported as the median and range. The dif-
ferences among the multiple groups and between two
groups (shown in Tables 1 and 2) were assessed using a
one-way analysis of variance (ANOVA) and Kruskal-Walls
H/Mann–Whitney U analysis, as appropriate. The differ-
ences in gender among the groups were compared using a
Chi-squared test. Spearman correlation analysis was used
to examine the correlation between serum amylase levels
and clinical characteristics. Stepwise regression was used
to select factors associated with the incidence of advanced
fibrosis in NAFLD patients. Multivariate logistic regres-
sion was used to examine the associations between the
amylase and the prevalence of advanced fibrosis in
NAFLD patients. All statistical tests were two-tailed. p <
0.05 was considered statistically significant.
Results
Baseline characteristics of study participants
The baseline characteristics of the study participants are
shown in Table 1. For the NAFLD with or without MS
groups, BMI, SBP, DBP, ALT, AST, γ-GT , TG, TC, HDL-C,
LDL-C, FPG, UA, amylase, HbA1C, HsCRP, PLT, and
FIB-4 values were all statistically different as comparedHealthy controls
(n = 304)
P value
ith MS (n = 300)
46.3 ± 12.2 46.3 ± 10.6 0.874
48/252* 110/194 <0.001
26.8 ± 2.5* 22.8 ± 2.6 <0.001
132 ± 16* 120 ± 14 <0.001
81 ± 11* 78 ± 10 <0.001
33 (9–184)* 17 (6–39) <0.001
26 (14–122)* 20 (12–38) <0.001
41 (7–236)* 18 (7–50) <0.001
.26 (0.63-21.05)* 0.97 (0.39–1.70) <0.001
5.06 ± 1.06* 4.51 ± 0.63 <0.001
1.01 ± 0.24* 1.27 ± 0.28 <0.001
2.62 ± 0.64* 2.49 ± 0.44 <0.001
.43 (4.23–16.46)* 4.76 (3.81–6.08) <0.001
76 (34–108)* 70 (40–104) <0.001
381 (146–547)* 309 (171–422) <0.001
42 (21–102)* 53 (7–122) <0.001
5.7 (4.6–12.5)* 5.5 (3.2–6.3) <0.001
1.6 (0.3–15.2)* 0.9 (0.2–8.8) <0.001
231 ± 55* 214 ± 41 <0.001
D with MS.
Table 2 Characteristics of NAFLD participants according to serum amylase quartile levels
Variables Total Q1 (Lowest) Q2 Q3 Q4 (Highest) P value
Amylase (U/L) 44 (21–207) 33 (21–37) 41 (38–44) 49 (45–53) 62 (54–207)
Age (yr) 46.1 ± 12.1 43.0 ± 11.0 45.5 ± 11.0 45.9 ± 11.9 50.5 ± 12.1 <0.001
Gender (female/male) 180/533 48/145 36/140 51/124 45/124 0.292
BMI (kg/m2) 26.2 ± 2.6 26.7 ± 3.0 26.3 ± 2.6 26.2 ± 2.5 25.6 ± 2.2 0.016
SBP (mmHg) 131 ± 16 132 ± 16 131 ± 15 131 ± 16 132 ± 17 0.804
DBP (mmHg) 80 ±11 80 ±11 81 ±11 80 ±11 80 ±10 0.460
ALT (IU/L) 29 (7–184) 30 (7–184) 33 (10–179) 28 (9–15) 26 (11–164) 0.011
AST (IU/L) 24 (12–122) 24 (12–103) 26 (15–122) 24 (13–55) 25 (15–101) 0.395
γ-GT (IU/L) 34 (7–248) 38 (8–236) 40 (9–248) 30 (11–145) 30 (7–139) <0.001
TG (mmol/L) 1.67 (0.34–21.05) 1.73 (0.34–15.86) 1.70 (0.41–21.05) 1.55 (0.47–10.91) 1.57 (0.37–7.77) 0.040
TC (mmol/L) 4.97 ± 0.98 4.92 ± 0.90 5.07 ± 1.16 4.97 ± 0.95 4.92 ± 0.89 0.444
HDL-c (mmol/L) 1.14 ± 0.32 1.13 ± 0.45 1.13 ± 0.27 1.16 ± 0.26 1.15 ± 0.24 0.709
LDL-c (mmol/L) 2.69 ± 0.61 2.63 ± 0.57 2.73 ± 0.64 2.72 ± 0.62 2.69 ± 0.60 0.364
FPG (mmol/L) 5.29 (3.82–16.46) 5.51 (3.82–16.46) 5.25 (4.25–14.25) 5.18 (4.23–7.61) 5.23 (4.22–12.42) <0.001
Cr (μmol/L) 74 (34–108) 73 (34–99) 73 (43–95) 72 (39–103) 75 (48–108) <0.001
UA (μmol/L) 363 (66–548) 368 (66–548) 377 (146–547) 357 (195–536) 353 (157–509) <0.001
Hba1C (%) 5.7 (4.2–12.5) 5.7 (4.8–10.5) 5.7 (4.2–12.5) 5.6 (4.7–7.8) 5.7 (4.6–11.5) 0.002
HsCRP (mg/L) 1.5 (0.3–19.4) 1.8 (0.4–16.5) 1.6 (0.3–19.0) 1.4 (0.4–19.4) 1.3 (0.3–17.0) <0.001
PLT (109/L) 233 ± 53 241 ± 50 228 ± 51 233 ± 52 228 ± 59 0.058
FIB-4 0.89 (0.26–4.61) 0.77 (0.26–2.94) 0.90 (0.26–4.61) 0.92 (0.33–3.21) 1.03 (0.27–4.50) <0.001
FIB-4 ≥ 1.3 (%) 156/713 (21.9) 27/193 (14.0) 37/176 (21.0) 37/175 (21.1) 55/169 (32.5) <0.001
MS (%) 300/713 (42.1) 96/193 (49.7) 81/176 (46.0) 55/175 (31.4) 68/169 (40.2) 0.003
Figure 1 Serum amylase levels in NAFLD patients with and
without MS/DM, FIB-4 ≥1.3 and <1.3.
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Moreover, for the NAFLD with MS group, BMI, ALT,
AST, γ-GT, TG, TC, HDL-C, LDL-C, FPG, UA, amylase,
HbA1C, HsCRP, and FIB-4 values were statistically differ-
ent from the NAFLD group without MS (P<0.05).
Serum amylase levels in NAFLD patients with MS/DM
were significantly lower than those in NAFLD patients
without MS/DM (both p < 0.05, Figure 1). Serum amylase
levels of the five MS components in NAFLD with MS pa-
tients are shown in Figure 2. Serum amylase levels of pa-
tients with elevated glucose, elevated TG, and low HDL-c
were significantly lower than in those with normal glu-
cose, TG, and HDL-c (p < 0.05). However, serum amylase
levels were not significantly different between normal and
elevated BMI or elevated BP patients (p > 0.05).
Characteristics of NAFLD participants according to the
quartile of amylase levels
We divided NAFLD participants into four groups: Q1
(lowest), Q2, Q3, and Q4 (highest) according to the quar-
tile of their serum amylase levels. Across increasing serum
amylase quartiles, BMI, SBP, DBP, TG, FPG, and HsCRP
levels were gradually decreased, while age, FIB-4 values
and the incidence of FIB-4 ≥ 1.3 gradually increased. Age,
Figure 2 Serum amylase levels of the five MS components in
NAFLD. a: fasting plasma glucose (FPG) ≥ 6.1 mmol/L or taking
anti-diabetic medications, b: blood pressure ≥ 140/90 mmHg or taking
anti-hypertensive medications, c: high density lipoprotein cholesterol
(HDL-c) < 0.9 mmol/L in males < 1.0 mmol/L in females.
Table 3 The correlation between serum amylase and
other covariates
Covariate Correlation coefficient P value
Age (yr) 0.212 <0.001
BMI (kg/m2) −0.163 0.001
SBP −0.024 0.541
DBP −0.027 0.479
ALT (IU/L) −0.101 0.007
AST (IU/L) 0.019 0.609
γ-GT (IU/L) −0.158 <0.001
TG (mmol/L) −0.108 0.004
TC (mmol/L) −0.023 0.541
HDL-c (mmol/L) 0.105 0.005
LDL-c (mmol/L) 0.027 0.465
FPG (mmol/L) −0.142 <0.001
Cr (μmol/L) 0.052 0.165
UA (μmol/L) −0.101 0.007
Hba1C (%) −0.058 0.122
HsCRP (mg/L) −0.177 <0.001
PLT (109/L) −0.116 0.002
FIB-4 0.233 <0.001
Table 4 Odds ratios for advanced fibrosis in NAFLD
participants according to serum amylase quartiles levels
(Q4 vs. Q1)
Model Odds ratio (95% CI) P value
Model 1 2.966 (2.199-4.002) <0.001
Model 2 1.798 (1.103-2.930) 0.019
Model 3 1.782 (1.090-2.911) 0.021
Model 4 1.840 (1.117-3.030) 0.017
Odds ratios were determined using logistic regression analyses. Model 1:
unadjusted; Model 2: adjusted for age, gender, and BMI; Model 3: adjusted for
age, gender, BMI, and history of MS; Model 4: adjusted for age, gender, BMI,
history of MS, γ-GT, ALT, and HsCRP.
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HsCRP, FIB-4 values, and the incidence of FIB-4 ≥ 1.3 and
MS were significantly different between the four groups.
Correlation analysis between serum amylase levels and
other variables
We found that the serum amylase levels in NAFLD
participants were positively correlated with age, HDL-c,
and FIB-4 (r > 0, p < 0.05) and negatively correlated
with BMI, ALT, γ-GT, TG, FPG, UA, and HsCRP (r < 0,
p < 0.05) (Table 3).
Association of serum amylase and the incidence of
advanced fibrosis in NAFLD participants
Serum amylase levels of the FIB-4 ≥ 1.3 group and the
FIB-4 < 1.3 group were significantly different (p = 0.004,
Figure 1). The results of an unadjusted and adjusted
multivariate logistic regression analysis model (model 1–4)
are presented in Table 4. Model 4, following adjustment
for age, gender, BMI, history of MS, γ-GT, ALT, and
HsCRP (p < 0.05 for all covariates), selected by stepwise
regression, showed that serum amylase levels were inde-
pendent factors predicting advanced fibrosis (FIB-4 ≥ 1.3)
in NAFLD participants (OR: 1.840, 95% CI: 1.117-3.030,
p = 0.017).
Discussion
The present cross-sectional study showed that NAFLD
patients with MS had lower serum amylase levels than
healthy controls and NAFLD patients without MS. The
prevalence of MS in NAFLD patients was higher in the
lower serum amylase levels group compared to the other
three groups. Moreover, serum amylase levels of NAFLD
patients with elevated FPG, elevated TG, or reduced
HDL-c levels were lower than in NAFLD patients withnormal FPG, TG, or HDL-c levels. In addition, serum
amylase levels were increased, as an independent factor,
in NAFLD patients with advanced liver fibrosis. These
results provide evidence for a significant association be-
tween low serum amylase levels and NAFLD with MS.
The significant association between low serum amylase
levels and NAFLD with MS suggest that MS and
NAFLD may both contribute to the decrease in serum
amylase levels. The potential mechanism accounting for
the association between NAFLD and low serum amylase
levels may be insulin resistance and fatty pancreas. Insu-
lin resistance is known to be one of the key components
of MS and it eventually leads to the development of type
2 diabetes, and NAFLD and NASH are tightly associated
with insulin resistance [22-26]. In humans, a strong rela-
tionship exists between hepatic fat accumulation and
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ance may enhance hepatic fat accumulation by increas-
ing free fatty acid delivery and by stimulating the
anabolic process due to hyperinsulinemia [34]. In 2014,
Gruben et al. [35] found that hepatic lipid accumulation
and inflammation could be the main drivers of hepatic
insulin resistance. The association between lipid accu-
mulation (such as diacylglycerol and TG) and hepatic in-
sulin resistance has been observed in some animal
models [36,37]. Although the physiological liver main-
tains blood glucose homeostasis by gluconeogenesis and
insulin inhibition, in hepatic insulin resistance, this in-
hibition is no longer effective [38]. Diacylglycerol is used
for the formation of TG, a process catalyzed by the en-
zyme diacylglycerol acyltransferase 2 (Dgat2), and lead-
ing to protein kinase Cε activation (PKCε), which in
turn results in hepatic insulin resistance [36,39]. Reduc-
tion of diacylglycerol by down-regulation of Dgat2 can
improve glucose intolerance and restore hepatic insulin
signaling in mice [36]. Main inflammatory pathways, nu-
clear factor κB (NF-κB) activation regulated by the IKK2
or TNFR signaling cascade, c-Jun NH2-terminal kinase
(JNK) activation, and Kupffer cell depletion are involved
in the development of insulin resistance [40-42].
Some studies reported the associations between low
serum amylase levels and MS, diabetes, NAFLD, cardio-
metabolic aspects, and insulin resistance after adjuste-
ment for relevant confounding factors [23,25,43,44].
These associations may be related to insulin resistance
and systemic ectopic fat deposition in the pancreas in
asymptomatic adults [45]. In rat models, long-term expos-
ure to a high-fat diet induced both interlobular and intra-
lobular fat accumulation, pancreas fibrosis, and damaged
the normal pancreatic architecture and islets [46]. In hu-
man studies, fatty pancreas is closely associated with in-
creased insulin resistance, metabolic syndrome, and fatty
liver [26]. NAFLD and MS have been reported to be asso-
ciated with fatty pancreas [47,48]. Some previous studies
have indicated that fatty pancreas may lead to exocrine-
endocrine dysfunction and to a loss of β-cell mass and
function [25,49], which may cause the decrease of serum
amylase [25]. Wu et al. found that serum amylase values
were significantly lower for the fatty pancreas as compared
to normal pancreas [26]. Lee et al., and our previous study,
also found that low serum amylase levels were associated
with an increased prevalence of MS [22,24]. Our results
are consistent with the studies of Nakajima et al. [23,25]
who also suggested that low serum amylase levels may be
associated with NAFLD and MS through insulin resist-
ance and fatty pancreas.
Liver biopsy is the gold standard for determining the
presence and degree of hepatic fibrosis in NAFLD pa-
tients, but liver biopsy has several shortcomings [50]. The
identification of advanced fibrosis in NAFLD patients isof utmost important in clinical practice [15]. Therefore,
non-invasive fibrosis models, such as APRI, BARD,
Hepascore, Fibrotest, FIB4, AAR, and NIKEI, were de-
veloped for evaluating advanced fibrosis in NAFLD
patients [14,15,51]. Xun et al., in China, showed that a
FIB-4 index ≥ 1.3 for evaluating advanced fibrosis was bet-
ter than the other non-invasive models and was suitable
for evaluating advanced fibrosis in Chinese NAFLD pa-
tients [15]. Therefore, we chose to use this index for
evaluating advanced fibrosis in our study.
NAFPD may lead to nonalcoholic steatopancreatitis
(NASP), and pancreatic steatosis has also become in-
creasingly and may affect the progression of NAFLD
[48,52,53]. Patel et al. found that pancreatic fat content
was lower in NAFLD patients who had advanced liver fi-
brosis as assessed by novel magnetic resonance imaging
technology [53]. Although serum amylase levels in
NAFLD patients were globally decreased, those NAFLD
patients with advanced fibrosis had relatively higher
serum amylase levels for less pancreatic fat content.
Similar to our results, Nakajima et al. suggested that low
serum amylase was associated with NAFLD independently
of MS, diabetes and obesity and may be an independent
marker for moderate/severe NAFLD in asymptomatic
adults [25]. However, in their study, it appears difficult to
evaluate the association between serum amylase and hep-
atic fibrosis since the study included a large number of
non-obese individuals with only a small proportion having
MS and diabetes, which may have resulted in a lower like-
lihood of advanced hepatic fibrosis.
Several limitations of our study should be mentioned.
First, it is a cross-sectional observational study that can-
not definitively comment on causality or temporal associ-
ation between low serum amylase and NAFLD. Second,
NAFLD diagnosis was based not on the gold standard of
liver biopsy, but on ultrasonography, which may not be
sensitive enough to detect mild steatosis. Third, for evalu-
ating advanced fibrosis, we did not use liver biopsy but the
surrogate FIB-4 index ≥ 1.3 [15]; it remains possible that
some patients were inadequately classified. Finally, we
only studied Chinese NAFLD patients and our results
may not fully apply to other ethnic populations.
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